PYY3-36 From the Gut Suppresses Appetite by Changing Brain Hunger Gene Expression
PYY3-36, a gut peptide released after eating, suppressed food intake in mice and altered hypothalamic neuropeptide expression, confirming it as a meal-derived satiety signal that changes brain hunger circuitry.
Quick Facts
What This Study Found
Peripheral PYY3-36 acutely suppressed food intake and altered hypothalamic neuropeptide expression (decreased NPY, increased POMC) in mice, confirming it as a gut-derived satiety signal that modulates central appetite gene programs.
Key Numbers
How They Did This
Animal study. PYY3-36 administered peripherally to mice. Food intake measured. Hypothalamic neuropeptide gene expression (NPY, POMC, AgRP, CART) analyzed by in situ hybridization.
Why This Research Matters
Understanding how gut satiety peptides change brain hunger genes enables development of more effective appetite-suppressing drugs that work at the gene expression level.
The Bigger Picture
Modern obesity drugs (GLP-1 agonists) target one gut satiety signal. PYY3-36 represents another parallel pathway. Combining multiple gut peptide signals could produce superior appetite control.
What This Study Doesn't Tell Us
Mouse study with acute PYY3-36 administration. Chronic effects may differ. Whether the gene expression changes persist is unknown.
Questions This Raises
- ?Could PYY3-36 analogs be developed as obesity drugs?
- ?Does combined GLP-1 + PYY therapy produce synergistic satiety?
- ?Are PYY levels deficient in obese individuals?
Trust & Context
- Key Stat:
- Gene reprogramming PYY3-36 didn't just suppress appetite temporarily — it decreased brain hunger genes (NPY) and increased satiety genes (POMC)
- Evidence Grade:
- Preliminary animal evidence with both behavioral and molecular endpoints confirming gut-brain appetite signaling.
- Study Age:
- Published in 2003. PYY-based approaches are being explored alongside GLP-1 for obesity treatment.
- Original Title:
- Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.
- Published In:
- Biochemical and biophysical research communications, 311(4), 915-9 (2003)
- Authors:
- Challis, B G, Pinnock, S B, Coll, A P, Carter, R N, Dickson, S L, O'Rahilly, S
- Database ID:
- RPEP-00804
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is PYY and how does it affect appetite?
PYY3-36 is a gut hormone released after eating that tells your brain you're full. This study shows it not only suppresses appetite but actually changes the brain's hunger gene activity.
Could this help with weight loss?
PYY-based drugs are being studied for obesity. They represent a different appetite pathway from GLP-1 drugs (like Ozempic), and combining them could provide more powerful appetite control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00804APA
Challis, B G; Pinnock, S B; Coll, A P; Carter, R N; Dickson, S L; O'Rahilly, S. (2003). Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.. Biochemical and biophysical research communications, 311(4), 915-9.
MLA
Challis, B G, et al. "Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.." Biochemical and biophysical research communications, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Acute effects of PYY3-36 on food intake and hypothalamic neu..." RPEP-00804. Retrieved from https://rethinkpeptides.com/research/challis-2003-acute-effects-of-pyy336
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.